外科理论与实践

外科理论与实践 >

2025 , Vol. 30 >Issue 04: 332 - 338

DOI: https://doi.org/10.16139/j.1007-9610.2025.04.07

论著

基于预后分析的肝内胆管癌肿瘤大小分型：一项回顾性多中心研究

  • 陈嘉倩 ,
  • 刘红枝 ,
  • 孟令甜 ,
  • 周伟平 ,
  • 程张军 ,
  • 楼健颖 ,
  • 郑树国 ,
  • 毕新宇 ,
  • 王剑明 ,
  • 郭伟 ,
  • 李富宇 ,
  • 王坚 ,
  • 郑亚民 ,
  • 李敬东 ,
  • 程石 ,
  • 黄尧 ,
  • 曾永毅
展开
  • 1.福建医科大学孟超肝胆医院肝胆外科，福建 福州 350001
    2.福州大学生物科学与工程学院，福建 福州 350108
    3.海军军医大学东方肝胆外科医院肝外三科，上海 200433
    4.东南大学附属中大医院肝胆胰外科，江苏 南京 210009
    5.浙江大学医学院附属第二医院肝胆胰外科，浙江 杭州 310009
    6.陆军军医大学西南医院胆道外科，重庆 400038
    7.中国医学科学院北京协和医学院肿瘤医院肝胆外科，北京 100021
    8.华中科技大学同济医学院附属同济医院胆胰外科，湖北 武汉 430030
    9.首都医科大学附属北京友谊医院普通外科，北京 100050
    10.四川大学华西医院胆道外科，四川 成都 610041
    11.上海交通大学医学院附属第六人民医院肝胆胰外科，上海 200233
    12.首都医科大学宣武医院普通外科，北京 100053
    13.川北医学院附属医院肝胆外科，四川 南充 637000
    14.首都医科大学附属北京天坛医院普通外科，北京 100070
曾永毅，E-mail: lamp197311@126.com

收稿日期: 2025-04-30

  网络出版日期: 2025-10-23

基金资助

福建省卫生健康委员会中青年科研重大项目(2021ZQNZD013);福州市卫生健康科技创新平台项目(2021-S-wp1)

收起

Intrahepatic cholangiocarcinoma tumor size classification based on prognostic analysis: a retrospective multicenter study

  • CHEN Jiaqian ,
  • LIU Hongzhi ,
  • MENG Lingtian ,
  • ZHOU Weiping ,
  • CHENG Zhangjun ,
  • LOU Jianying ,
  • ZHENG Shuguo ,
  • BI Xinyu ,
  • WANG Jianming ,
  • GUO Wei ,
  • LI Fuyu ,
  • WANG Jian ,
  • ZHENG Yamin ,
  • LI Jingdong ,
  • CHENG Shi ,
  • HUANG Yao ,
  • ZENG Yongyi
Expand
  • 1. Department of Hepatobiliary Surgery, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fujian Fuzhou 350001, China
    2. Fuzhou University, College of Biological Sciences and Engineering, Fujian Fuzhou 350108, China
    3. Department of Hapatic Surgery Ⅲ, Eastern Hepatobiliary Surgery Hospital of Naval Medical University, Shanghai 200433, China
    4. Department of Hepatobiliary and Pancreatic Surgery, Zhongda Hospital, Southeast University, Jiangsu Nanjing 210009, China
    5. Department of Hepatobiliary and Pancreatic Surgery, the Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang Hangzhou 310009, China
    6. Department of Biliary Surgery, the Southwest Hospital of Army Medical University, Chongqing 400038, China
    7. Department of Hepatobiliary Surgery, Cancer Hospital, Peking Union Medical University, Chinese Academy of Medical Sciences, Beijing 100021, China
    8. Department of Biliary and Pancreatic Surgery, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Hubei Wuhan 430030, China
    9. Department of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
    10. Department of Biliary Surgery, West China Hospital, Sichuan University, Sichuan Chengdu 610041, China
    11. Department of Hepatobiliary and Pancreatic Surgery, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai 200233, China
    12. Department of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, China
    13. Department of Hepatobiliary Surgery, Affiliated Hospital of North Sichuan Medical College, Sichuan Nanchong 637000, China
    14. Department of General Surgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China

Received date: 2025-04-30

  Online published: 2025-10-23

Fold

摘要

目的：基于国内多中心临床病理数据进行回顾性分析，探讨肝内胆管癌（ICC）肿瘤大小分型与其预后的相关性，建立基于肿瘤大小的分型系统。方法：纳入2011年12月至2018年9月来自13家医院的280例ICC病人，采用最小P值法分析明确肿瘤大小的预后临界值，通过Kaplan-Meier法验证此分型在总生存率的效能。结果：共280例以最大径4 cm为界分为≤ 4 cm组、>4 cm组。通过多因素COX回归分析证实肿瘤大小分型是独立预后因素（HR=2.110，95% CI: 1.358~3.280）。结论：基于中国病人群体的肿瘤大小二分类系统方便有效地区分ICC的预后分层，为术后个性化辅助治疗、随访方案的选择提供了重要依据。

关键词： 肝内胆管癌; 肿瘤大小; 预后; 回顾性研究

本文引用格式

陈嘉倩 , 刘红枝 , 孟令甜 , 周伟平 , 程张军 , 楼健颖 , 郑树国 , 毕新宇 , 王剑明 , 郭伟 , 李富宇 , 王坚 , 郑亚民 , 李敬东 , 程石 , 黄尧 , 曾永毅 . 基于预后分析的肝内胆管癌肿瘤大小分型：一项回顾性多中心研究[J]. 外科理论与实践, 2025 , 30(04) : 332 -338 . DOI: 10.16139/j.1007-9610.2025.04.07

Abstract

Objective To retrospectively analyze multicenter data from domestic sources, aiming to explore the link between intrahepatic cholangiocarcinoma (ICC) tumor size and prognosis, establishing a classification system based on tumor size. Methods Between December 2011 and September 2018, 280 ICC patients from 13 hospitals were included. The tumor size prognosis cutoff was identified by the minimum P-value method, and the classification's overall survival related effectiveness was assessed by Kaplan-Meier analysis. Results All 280 patients were divided into the group of tumor maximum diameter ≤4 cm and >4 cm. Tumor size was confirmed as an independent prognosis factor by multivariate COX regression analysis (HR=2.110, 95% CI: 1.358-3.280). Conclusions The tumor size dichotomy classification system based on the Chinese patient group can expediently predict ICC prognosis and offers an important basis for selecting post-operative individualized adjuvant therapy and follow up plans.

Key words： Intrahepatic cholangiocarcinoma (ICC); Tumor size; Prognosis; Retrospective Study

参考文献

[1] XIA C, DONG X, LI H, et al. Cancer statistics in China and United States,2022:profiles, trends, and determinants[J]. Chin Med J(Engl), 2022, 135(5):584-590.
[2] MASSARWEH N N, EL-SERAG H B. Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma[J]. Cancer Control, 2017, 24(3):1073274817729245.
[3] BENSON A B, D’ANGELICA M I, ABBOTT D E, et al. Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2021, 19(5):541-565.
[4] 中国抗癌协会肝癌专业委员会胆管癌协作组. 原发性肝癌诊疗指南之肝内胆管癌诊疗中国专家共识(2022版)[J]. 中华消化外科杂志, 2022, 21(10):1269-1301.
  Chinese Society of Liver Cancer Cholangiocarcinoma Cooperative Group. Chinese expert consensus on management of intrahepatic cholangiocarcinoma (2022 edition)[J]. Chin J Dig Surg, 2022, 21(10):1269-1301.
[5] KANG S H, HWANG S, LEE Y J, et al. Prognostic comparison of the 7th and 8th editions of the American joint committee on cancer staging system for intrahepatic cho-langiocarcinoma[J]. J Hepatobiliary Pancreat Sci, 2018, 25(4):240-248.
[6] SPOLVERATO G, BAGANTE F, WEISS M, et al. Comparative performances of the 7th and the 8th editions of the American joint committee on cancer staging systems for intrahepatic cholangiocarcinoma[J]. J Surg Oncol, 2017, 115(6):696-703.
[7] HUANG G, XI P, YAO Z, et al. The clinical association between the inflammation-nutritional condition and prognosis of locally advanced intrahepatic cholangiocarcinoma after R0 resection: evidence from competing risk and propensity matching analysis[J]. J Inflamm Res, 2024,17:2787-2799.
[8] XIE H, HONG T, LIU W, et al. Interpretable machine learning-based clinical prediction model for predicting lymph node metastasis in patients with intrahepatic cho-langiocarcinoma[J]. BMC gastroenterology, 2024, 24(1):137.
[9] BAI S, SHI X, DAI Y, et al. The preoperative scoring system combining neutrophil/lymphocyte ratio and CA19-9 predicts the long-term prognosis of intrahepatic cholangiocarcinoma patients undergoing curative liver resection[J]. BMC cancer, 2024, 24(1):1106.
[10] LAMARCA A, SANTOS-LASO A, UTPATEL K, et al. Liver metastases of intrahepatic cholangiocarcinoma: implications for an updated staging system[J]. Hepatology, 2021, 73(6):2311-2325.
[11] SAKAMOTO Y, KOKUDO N, MATSUYAMA Y, et al. Proposal of a new staging system for intrahepatic cholangiocarcinoma: analysis of surgical patients from a nationwide survey of the liver cancer study group of Japan[J]. Cancer, 2016, 122(1):61-70.
[12] KUBO S, SHINKAWA H, ASAOKA Y, et al. Liver cancer study group of Japan clinical practice guidelines for intrahepatic cholangiocarcinoma[J]. Liver Cancer, 2022, 11(4):290-314.
[13] 梁煜, 赵远红, 李正内, 等. 肝内胆管癌的危险因素与发病机制[J]. 临床肝胆病杂志, 2022, 38(10):2391-2395.
  LIANG Y, ZHAO Y H, LI Z N, et al. Recent advancement in research on intrahepatic cholangiocarcinoma:risk factors and pathogenesis[J]. J Clin Hepatol, 2022, 38(10):2391-2395.
[14] CONNOR A A, KODALI S, ABDELRAHIM M, et al. Intrahepatic cholangiocarcinoma: the role of liver transplantation, adjunctive treatments, and prognostic biomarkers[J]. Front Oncol, 2022,12:996710.
[15] BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3):229-263.
[16] MORIS D, PALTA M, KIM C, et al. Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians[J]. CA Cancer J Clin, 2023, 73(2):198-222.
[17] 安澜, 曾红梅, 冉显会, 等. 肝细胞癌和肝内胆管细胞癌流行病学研究进展[J]. 中国肿瘤, 2020, 29(11):879-884.
  AN L, ZENG H M, RAN X H, et al. Progress on epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma[J]. China Cancer, 2020, 29(11):879-884.
[18] ELVEVI A, LAFFUSA A, SCARAVAGLIO M, et al. Clinical treatment of cholangiocarcinoma: an updated comprehensive review[J]. Ann Hepatol, 2022, 27(5):100737.
[19] KHAN S A, TAVOLARI S, BRANDI G. Cholangiocarcinoma: epidemiology and risk factors[J]. Liver Int, 2019, 39(Suppl 1):19-31.
[20] 胡笛, 黄金涛, 仲斌演, 等. 肝内胆管癌的诊疗进展[J]. 临床肝胆病杂志, 2024, 40(7):1470-1476.
  HU D, HUANG J T, ZHONG B Y, et al. Advances in the diagnosis and treatment of intrahepatic cholangiocarcinoma[J]. J Clin Hepatol, 2024, 40(7):1470-1476.
[21] ALAIMO L, BOGGIO S, CATALANO G, et al. Multi-omics classification of intrahepatic cholangiocarcinoma: a systematic review and meta-analysis[J]. Cancers(Basel), 2024, 16(14):2596.
[22] CHANG Y J, CHANG Y J, CHEN L J. Prognostic factors in patients with intrahepatic cholangiocarcinoma[J]. Sci Rep, 2024, 14(1):19084.
[23] CHUN Y S, JAVLE M. Systemic and adjuvant therapies for intrahepatic cholangiocarcinoma[J]. Cancer Control, 2017, 24(3):1073274817729241.
[24] VAN KEULEN A M, BüTTNER S, ERDMANN J I, et al. Major complications and mortality after resection of intrahepatic cholangiocarcinoma: a systematic review and meta-analysis[J]. Surgery, 2023, 173(4):973-982.
[25] TSILIMIGRAS D I, SAHARA K, WU L, et al. Very early recurrence after liver resection for intrahepatic cholangiocarcinoma: considering alternative treatment approaches[J]. JAMA Surg, 2020, 155(9):823-831.
[26] JI G W, JIAO C Y, XU Z G, et al. Development and validation of a gradient boosting machine to predict prognosis after liver resection for intrahepatic cholangiocarcinoma[J]. BMC cancer, 2022, 22(1):258.
[27] BAGANTE F, SPOLVERATO G, MERATH K, et al. Intrahepatic cholangiocarcinoma tumor burden: a classification and regression tree model to define prognostic groups after resection[J]. Surgery, 2019, 166(6):983-990.
[28] LI Y, TANG C, ZHAO B, et al. Redefining the T1 ca-tegory of the 8th American joint committee on cancer staging system for intrahepatic cholangiocarcinoma: a SEER database analysis[J]. Oncol Lett, 2020, 19(1):527-532.
[29] LIU Y G, JIANG S T, ZHANG J W, et al. Development and validation of web-based nomograms for predicting survival status in patients with intrahepatic cholangiocarcinoma depending on the surgical status: a SEER database analysis[J]. Sci Rep, 2024, 14(1):1568.
[30] AMIN M B, GREENE F L, EDGE S B, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging[J]. CA Cancer J Clin, 2017, 67(2):93-99.
[31] KONG J, CAO Y, CHAI J, et al. Effect of tumor size on long-term survival after resection for solitary intrahepatic cholangiocarcinoma[J]. Front Oncol, 2021,10:559911.
[32] GALASSI C, CHAN T A, VITALE I, et al. The hallmarks of cancer immune evasion[J]. Cancer Cell, 2024, 42(11):1825-1863.
Options
文章导航

/

〈 〉